WWOX at the crossroads of cancer, metabolic syndrome related traits and CNS pathologies

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1846, Issue 1, 2014, Pages 188-200

  Aldaz, C Marcelo ^a   Ferguson, Brent W ^a   Abba, Martin C ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

Author keywords

Epilepsy; FRA16D; Lipid metabolism; TGF ; WNT; WWOX

Indexed keywords

ADENINE; CYTOSINE; GUANINE; MESSENGER RNA; SMAD3 PROTEIN; THYMINE; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN; SMAD PROTEIN;

ATAXIA; BREAST CANCER; CANCER PROGNOSIS; CENTRAL NERVOUS SYSTEM DISEASE; CHROMOSOME FRAGILE SITE; DYSLIPIDEMIA; ENDOMETRIUM CARCINOMA; EPILEPSY; GENE DELETION; GENE FREQUENCY; GENE FUNCTION; GENE LOCUS; GENE MAPPING; GENE TRANSLOCATION; GENETIC ASSOCIATION; GENETIC CONSERVATION; GERMLINE MUTATION; HEAD AND NECK CANCER; HOMOZYGOSITY; HUMAN; INTRACELLULAR SIGNALING; LIPID METABOLISM; LOSS OF FUNCTION MUTATION; MALIGNANT NEOPLASTIC DISEASE; MENTAL DEFICIENCY; METABOLIC SYNDROME X; MOLECULAR CLONING; MULTIPLE MYELOMA; NEUROPATHOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REVIEW; SOMATIC MUTATION; STOMACH ADENOCARCINOMA; TUMOR SUPPRESSOR GENE; WWOX GENE; BREAST CARCINOMA; DISEASE ASSOCIATION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HETEROZYGOSITY; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; MISSENSE MUTATION; MOLECULAR EVOLUTION; NEOPLASM; PROTEIN BINDING; PROTEIN DOMAIN; QUANTITATIVE TRAIT LOCUS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR ABLATION; UBIQUITINATION;

EPILEPSY; FRA16D; LIPID METABOLISM; TGFΒ; WNT; WWOX;

ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; EVOLUTION, MOLECULAR; HUMANS; METABOLIC SYNDROME X; MICE; MUTATION; NEOPLASMS; OXIDOREDUCTASES; QUANTITATIVE TRAIT LOCI; TUMOR SUPPRESSOR PROTEINS;

EID: 84905222850     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.06.001     Document Type: Review

References (110)

1. Chen T., Sahin A., Aldaz C.M. Deletion map of chromosome 16q in ductal carcinoma in situ of the breast: refining a putative tumor suppressor gene region. Cancer Res. 1996, 56(24):5605-5609.
2. Bednarek A.K., Laflin K.J., Daniel R.L., Liao Q., Hawkins K.A., Aldaz C.M. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res. 2000, 60(8):2140-2145.
3. Chesi M., Bergsagel P.L., Shonukan O.O., Martelli M.L., Brents L.A., Chen T., et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 1998, 91(12):4457-4463.
4. Ried K., Finnis M., Hobson L., Mangelsdorf M., Dayan S., Nancarrow J.K., et al. Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum. Mol. Genet. 2000, 9(11):1651-1663.
5. Chang N.S., Pratt N., Heath J., Schultz L., Sleve D., Carey G.B., et al. Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J. Biol. Chem. 2001, 276(5):3361-3370.
6. Krummel K.A., Denison S.R., Calhoun E., Phillips L.A., Smith D.I. The common fragile site FRA16D and its associated gene WWOX are highly conserved in the mouse at Fra8E1. Gene Chromosome Cancer 2002, 34(2):154-167.
7. Calin G.A., Sevignani C., Dumitru C.D., Hyslop T., Noch E., Yendamuri S., et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(9):2999-3004.
8. Calin G.A., Liu C.G., Ferracin M., Hyslop T., Spizzo R., Sevignani C., et al. Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell 2007, 12(3):215-229.
9. Pennacchio L.A., Ahituv N., Moses A.M., Prabhakar S., Nobrega M.A., Shoukry M., et al. In vivo enhancer analysis of human conserved non-coding sequences. Nature 2006, 444(7118):499-502.
10. Gilad Y., Oshlack A., Smyth G.K., Speed T.P., White K.P. Expression profiling in primates reveals a rapid evolution of human transcription factors. Nature 2006, 440(7081):242-245.
11. Nunez M., Ludes-Meyers J., Aldaz C. WWOX protein expression in normal human tissues. J. Mol. Hist. 2006, 37:115-125.
12. Guler G., Uner A., Guler N., Han S.Y., Iliopoulos D., Hauck W.W., et al. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer 2004, 100(8):1605-1614.
13. Nunez M.I., Ludes-Meyers J., Abba M.C., Kil H., Abbey N.W., Page R.E., et al. Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status. Breast Cancer Res. Treat. 2005, 89(2):99-105.
14. Nunez M.I., Rosen D.G., Ludes-Meyers J.H., Abba M.C., Kil H., Page R., et al. WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC Cancer 2005, 5:64.
15. Aqeilan R.I., Kuroki T., Pekarsky Y., Albagha O., Trapasso F., Baffa R., et al. Loss of WWOX expression in gastric carcinoma. Clin. Cancer Res. 2004, 10(9):3053-3058.
16. Park S.W., Ludes-Meyers J., Zimonjic D.B., Durkin M.E., Popescu N.C., Aldaz C.M. Frequent downregulation and loss of WWOX gene expression in human hepatocellular carcinoma. Br. J. Cancer 2004, 91(4):753-759.
17. Donati V., Fontanini G., Dell'Omodarme M., Prati M.C., Nuti S., Lucchi M., et al. WWOX expression in different histologic types and subtypes of non-small cell lung cancer. Clin. Cancer Res. 2007, 13(3):884-891.
18. Dias E.P., Pimenta F.J., Sarquis M.S., Dias Filho M.A., Aldaz C.M., Fujii J.B., et al. Association between decreased WWOX protein expression and thyroid cancer development. Thyroid 2007, 17(11):1055-1059.
19. Bloomston M., Kneile J., Butterfield M., Dillhoff M., Muscarella P., Ellison E.C., et al. Coordinate loss of fragile gene expression in pancreatobiliary cancers: correlations among markers and clinical features. Ann. Surg. Oncol. 2009, 16(8):2331-2338.
20. Paige A.J., Taylor K.J., Taylor C., Hillier S.G., Farrington S., Scott D., et al. WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(20):11417-11422.
21. Gardenswartz A., Aqeilan R.I. WW domain-containing oxidoreductase's role in myriad cancers: clinical significance and future implications. Exp. Biol. Med. 2014, 239(3):253-263.
22. Ramos D., Abba M., Lopez-Guerrero J.A., Rubio J., Solsona E., Almenar S., et al. Low levels of WWOX protein immunoexpression correlate with tumour grade and a less favourable outcome in patients with urinary bladder tumours. Histopathology 2008, 52(7):831-839.
23. Bednarek A.K., Keck-Waggoner C.L., Daniel R.L., Laflin K.J., Bergsagel P.L., Kiguchi K., et al. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res. 2001, 61(22):8068-8073.
24. Driouch K., Prydz H., Monese R., Johansen H., Lidereau R., Frengen E. Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors. Oncogene 2002, 21(12):1832-1840.
25. Iliopoulos D., Guler G., Han S.Y., Johnston D., Druck T., McCorkell K.A., et al. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene 2005, 24(9):1625-1633.
26. Mahajan N.P., Whang Y.E., Mohler J.L., Earp H.S. Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox. Cancer Res. 2005, 65(22):10514-10523.
27. Abu-Odeh M., Bar-Mag T., Huang H., Kim T., Salah Z., Abdeen S.K., et al. Characterizing WW domain interactions of tumor suppressor WWOX reveals its association with multiprotein networks. J. Biol. Chem. Mar 28 2014, 289(13):8865-8880.
28. Liu C.J., Shen W.G., Peng S.Y., Cheng H.W., Kao S.Y., Lin S.C., et al. miR-134 induces oncogenicity and metastasis in head and neck carcinoma through targeting WWOX gene. Int. J. Cancer 2014, 134(4):811-821.
29. Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., et al. Signatures of mutation and selection in the cancer genome. Nature 2010, 463(7283):893-898.
30. Beroukhim R., Mermel C.H., Porter D., Wei G., Raychaudhuri S., Donovan J., et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463(7283):899-905.
31. Beroukhim R., Getz G., Nghiemphu L., Barretina J., Hsueh T., Linhart D., et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(50):20007-20012.
32. Cerami E., Gao J., Dogrusoz U., Gross B.E., Sumer S.O., Aksoy B.A., et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012, 2(5):401-404.
33. Gao J., Aksoy B.A., Dogrusoz U., Dresdner G., Gross B., Sumer S.O., et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 2013, 6(269):pl1. (1-19).
34. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474(7353):609-615.
35. Cancer Genome Atlas Research Network Comprehensive molecular portraits of human breast tumours. Nature 2012, 490(7418):61-70.
36. Cancer Genome Atlas Research Network Integrated genomic characterization of endometrial carcinoma. Nature 2013, 497(7447):67-73.
37. Cancer Genome Atlas Research Network Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487(7407):330-337.
38. Gyorffy B., Lanczky A., Szallasi Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr. Relat. Cancer 2012, 19(2):197-208.
39. Stransky N., Egloff A.M., Tward A.D., Kostic A.D., Cibulskis K., Sivachenko A., et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011, 333(6046):1157-1160.
40. Reva B., Antipin Y., Sander C. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res. 2011, 39(17):e118.
41. Bergsagel P.L., Kuehl W.M. Chromosome translocations in multiple myeloma. Oncogene 2001, 20(40):5611-5622.
42. Sawyer J.R., Lukacs J.L., Munshi N., Desikan K.R., Singhal S., Mehta J., et al. Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood 1998, 92(11):4269-4278.
43. Nagoshi H., Taki T., Hanamura I., Nitta M., Otsuki T., Nishida K., et al. Frequent PVT1 rearrangement and novel chimeric genes PVT1-NBEA and PVT1-WWOX occur in multiple myeloma with 8q24 abnormality. Cancer Res. 2012, 72(19):4954-4962.
44. Carrasco D.R., Tonon G., Huang Y., Zhang Y., Sinha R., Feng B., et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006, 9(4):313-325.
45. Jenner M.W., Leone P.E., Walker B.A., Ross F.M., Johnson D.C., Gonzalez D., et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood 2007, 110(9):3291-3300.
46. Agnelli L., Mosca L., Fabris S., Lionetti M., Andronache A., Kwee I., et al. A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect. Gene Chromosome Cancer 2009, 48(7):603-614.
47. Walker B.A., Leone P.E., Chiecchio L., Dickens N.J., Jenner M.W., Boyd K.D., et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 2010, 116(15):e56-e65.
48. Dickens N.J., Walker B.A., Leone P.E., Johnson D.C., Brito J.L., Zeisig A., et al. Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clin. Cancer Res. 2010, 16(6):1856-1864.
49. Ludes-Meyers J.H., Kil H., Nunez M.I., Conti C.J., Parker-Thornburg J., Bedford M.T., et al. WWOX hypomorphic mice display a higher incidence of B-cell lymphomas and develop testicular atrophy. Gene Chromosome Cancer 2007, 46(12):1129-1136.
50. Aqeilan R., Trapasso F., Hussain S., Costinean S., Marshall D., Pekarsky Y., et al. Targeted deletion of Wwox reveals a tumor suppressor function. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(10):3949-3954.
51. Ludes-Meyers J.H., Kil H., Parker-Thornburg J., Kusewitt D.F., Bedford M.T., Aldaz C.M. Generation and characterization of mice carrying a conditional allele of the Wwox tumor suppressor gene. PLoS ONE 2009, 4(11):e7775.
52. Aqeilan R.I., Hagan J.P., de Bruin A., Rawahneh M., Salah Z., Gaudio E., et al. Targeted ablation of the WW domain-containing oxidoreductase tumor suppressor leads to impaired steroidogenesis. Endocrinology 2009, 150(3):1530-1535.
53. Aqeilan R.I., Hagan J.P., Aqeilan H.A., Pichiorri F., Fong L.Y., Croce C.M. Inactivation of the Wwox gene accelerates forestomach tumor progression in vivo. Cancer Res. 2007, 67(12):5606-5610.
54. Abdeen S.K., Salah Z., Maly B., Smith Y., Tufail R., Abu-Odeh M., et al. Wwox inactivation enhances mammary tumorigenesis. Oncogene 2011, 30(36):3900-3906.
55. Ferguson B.W., Gao X., Kil H., Lee J., Benavides F., Abba M.C., et al. Conditional Wwox deletion in mouse mammary gland by means of two Cre recombinase approaches. PLoS ONE 2012, 7(5):e36618.
56. Roarty K., Serra R. Wnt5a is required for proper mammary gland development and TGF-beta-mediated inhibition of ductal growth. Development 2007, 134(21):3929-3939.
57. Katoh M. STAT3-induced WNT5A signaling loop in embryonic stem cells, adult normal tissues, chronic persistent inflammation, rheumatoid arthritis and cancer (Review). Int. J. Mol. Med. 2007, 19(2):273-278.
58. Iatan I., Choi H.Y., Ruel I., Reddy M.P., Hyunsuk K., Lee J., et al. The WWOX Gene Modulates HDL and Lipid Metabolism. Circ. Cardiovasc. Genet. May 28 2014, ([Epub ahead of print] PMID: 24871327).
59. Ludes-Meyers J.H., Bednarek A.K., Popescu N.C., Bedford M., Aldaz C.M. WWOX, the common chromosomal fragile site, FRA16D, cancer gene. Cytogenet. Genome Res. 2003, 100(1-4):101-110.
60. Chang N.S., Doherty J., Ensign A., Schultz L., Hsu L.J., Hong Q. WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds and stabilizes serine 46-phosphorylated p53. J. Biol. Chem. 2005, 280(52):43100-43108.
61. Sudol M., Hunter T. NeW wrinkles for an old domain. Cell 2000, 103(7):1001-1004.
62. Ludes-Meyers J.H., Kil H., Bednarek A.K., Drake J., Bedford M.T., Aldaz C.M. WWOX binds the specific proline-rich ligand PPXY: identification of candidate interacting proteins. Oncogene 2004, 23(29):5049-5055.
63. Aqeilan R.I., Palamarchuk A., Weigel R.J., Herrero J.J., Pekarsky Y., Croce C.M. Physical and functional interactions between the Wwox tumor suppressor protein and the AP-2gamma transcription factor. Cancer Res. 2004, 64(22):8256-8261.
64. Schuchardt B.J., Bhat V., Mikles D.C., McDonald C.B., Sudol M., Farooq A. Molecular origin of the binding of WWOX tumor suppressor to ErbB4 receptor tyrosine kinase. Biochemistry 2013, 52(51):9223-9236.
65. Salah Z., Aqeilan R., Huebner K. WWOX gene and gene product: tumor suppression through specific protein interactions. Future Oncol. 2010, 6(2):249-259.
66. Aqeilan R.I., Pekarsky Y., Herrero J.J., Palamarchuk A., Letofsky J., Druck T., et al. Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(13):4401-4406.
67. Salah Z., Bar-mag T., Kohn Y., Pichiorri F., Palumbo T., Melino G., et al. Tumor suppressor WWOX binds to DeltaNp63alpha and sensitizes cancer cells to chemotherapy. Cell Death Dis. 2013, 4:e480.
68. Bouteille N., Driouch K., Hage P.E., Sin S., Formstecher E., Camonis J., et al. Inhibition of the Wnt/beta-catenin pathway by the WWOX tumor suppressor protein. Oncogene 2009, 28(28):2569-2580.
69. Fabbri M., Iliopoulos D., Trapasso F., Aqeilan R., Cimmino A., Zanesi N., et al. WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(43):15611-15616.
70. Qin H.R., Iliopoulos D., Semba S., Fabbri M., Druck T., Volinia S., et al. A role for the WWOX gene in prostate cancer. Cancer Res. 2006, 66(13):6477-6481.
71. Iliopoulos D., Fabbri M., Druck T., Qin H.R., Han S.Y., Huebner K. Inhibition of breast cancer cell growth in vitro and in vivo: effect of restoration of Wwox expression. Clin. Cancer Res. 2007, 13(1):268-274.
72. Gourley C., Paige A.J., Taylor K.J., Ward C., Kuske B., Zhang J., et al. WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3. Cancer Res. 2009, 69(11):4835-4842.
73. Becker S., Markova B., Wiewrodt R., Hoffarth S., Hahnel P.S., Pleiner S., et al. Functional and clinical characterization of the putative tumor suppressor WWOX in non-small cell lung cancer. J. Thorac. Oncol. 2011, 6(12):1976-1983.
74. Stuart J.M., Segal E., Koller D., Kim S.K. A gene-coexpression network for global discovery of conserved genetic modules. Science 2003, 302(5643):249-255.
75. Oti M., van Reeuwijk J., Huynen M.A., Brunner H.G. Conserved co-expression for candidate disease gene prioritization. BMC Bioinformatics 2008, 9:208.
76. Bindea G., Mlecnik B., Hackl H., Charoentong P., Tosolini M., Kirilovsky A., et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 2009, 25(8):1091-1093.
77. Bindea G., Galon J., Mlecnik B. CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data. Bioinformatics 2013, 29(5):661-663.
78. Lachmann A., Xu H., Krishnan J., Berger S.I., Mazloom A.R., Ma'ayan A. ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments. Bioinformatics 2010, 26(19):2438-2444.
79. Silberstein G.B., Daniel C.W. Reversible inhibition of mammary gland growth by transforming growth factor-beta. Science 1987, 237(4812):291-293.
80. Silberstein G.B., Flanders K.C., Roberts A.B., Daniel C.W. Regulation of mammary morphogenesis: evidence for extracellular matrix-mediated inhibition of ductal budding by transforming growth factor-beta 1. Dev. Biol. 1992, 152(2):354-362.
81. Ferguson B.W., Gao X., Zelazowski M.J., Lee J., Jeter C.R., Abba M.C., et al. The cancer gene WWOX behaves as an inhibitor of SMAD3 transcriptional activity via direct binding. BMC Cancer 2013, 13:593.
82. Chen C.R., Kang Y., Siegel P.M., Massague J. E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. Cell 2002, 110(1):19-32.
83. Feng X.H., Liang Y.Y., Liang M., Zhai W., Lin X. Direct interaction of c-Myc with Smad2 and Smad3 to inhibit TGF-beta-mediated induction of the CDK inhibitor p15(Ink4B). Mol. Cell 2002, 9(1):133-143.
84. Pardali K., Kurisaki A., Moren A., ten Dijke P., Kardassis D., Moustakas A. Role of Smad proteins and transcription factor Sp1 in p21(Waf1/Cip1) regulation by transforming growth factor-beta. J. Biol. Chem. 2000, 275(38):29244-29256.
85. Barcellos-Hoff M.H., Akhurst R.J. Transforming growth factor-beta in breast cancer: too much, too late. Breast Cancer Res. 2009, 11(1):202.
86. Moses H., Barcellos-Hoff M.H. TGF-beta biology in mammary development and breast cancer. Cold Spring Harb. Perspect. Biol. 2011, 3(1):a003277.
87. Padua D., Massague J. Roles of TGFbeta in metastasis. Cell Res. 2009, 19(1):89-102.
88. Massague J. TGFbeta signalling in context. Nat. Rev. Mol. Cell Biol. 2012, 13(10):616-630.
89. Aragon E., Goerner N., Xi Q., Gomes T., Gao S., Massague J., et al. Structural basis for the versatile interactions of Smad7 with regulator WW domains in TGF-beta Pathways. Structure 2012, 20(10):1726-1736.
90. Lee J.C., Weissglas-Volkov D., Kyttala M., Dastani Z., Cantor R.M., Sobel E.M., et al. WW-domain-containing oxidoreductase is associated with low plasma HDL-C levels. Am. J. Hum. Genet. 2008, 83(2):180-192.
91. Willer C.J., Sanna S., Jackson A.U., Scuteri A., Bonnycastle L.L., Clarke R., et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat. Genet. 2008, 40(2):161-169.
92. Saez M.E., Gonzalez-Perez A., Martinez-Larrad M.T., Gayan J., Real L.M., Serrano-Rios M., et al. WWOX gene is associated with HDL cholesterol and triglyceride levels. BMC Med. Genet. 2010, 11:148.
93. Leduc M.S., Lyons M., Darvishi K., Walsh K., Sheehan S., Amend S., et al. The mouse QTL map helps interpret human genome-wide association studies for HDL cholesterol. J. Lipid Res. 2011, 52(6):1139-1149.
94. Chang Y.C., Chiu Y.F., Liu P.H., Shih K.C., Lin M.W., Sheu W.H., et al. Replication of genome-wide association signals of type 2 diabetes in Han Chinese in a prospective cohort. Clin. Endocrinol. 2012, 76(3):365-372.
95. Sakai K., Imamura M., Tanaka Y., Iwata M., Hirose H., Kaku K., et al. Replication study for the association of 9 East Asian GWAS-derived loci with susceptibility to type 2 diabetes in a Japanese population. PLoS ONE 2013, 8(9):e76317.
96. Yang H.C., Liang Y.J., Chen J.W., Chiang K.M., Chung C.M., Ho H.Y., et al. Identification of IGF1, SLC4A4, WWOX, and SFMBT1 as hypertension susceptibility genes in Han Chinese with a genome-wide gene-based association study. PLoS ONE 2012, 7(3):e32907.
97. Polfus L.M., Smith J.A., Shimmin L.C., Bielak L.F., Morrison A.C., Kardia S.L., et al. Genome-wide association study of gene by smoking interactions in coronary artery calcification. PLoS ONE 2013, 8(10):e74642.
98. Wang K., Li W.D., Zhang C.K., Wang Z., Glessner J.T., Grant S.F., et al. A genome-wide association study on obesity and obesity-related traits. PLoS ONE 2011, 6(4):e18939.
99. Vasan R.S., Glazer N.L., Felix J.F., Lieb W., Wild P.S., Felix S.B., et al. Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data. JAMA 2009, 302(2):168-178.
100. Gribaa M., Salih M., Anheim M., Lagier-Tourenne C., H'Mida D., Drouot N., et al. A new form of childhood onset, autosomal recessive spinocerebellar ataxia and epilepsy is localized at 16q21-q23. Brain 2007, 130(Pt 7):1921-1928.
101. Mallaret M., Synofzik M., Lee J., Sagum C.A., Mahajnah M., Sharkia R., et al. The tumour suppressor gene WWOX is mutated in autosomal recessive cerebellar ataxia with epilepsy and mental retardation. Brain 2014, 137(Pt 2):411-419.
102. Abdel-Salam G., Thoenes M., Afifi H.H., Korber F., Swan D., Bolz H.J. The supposed tumor suppressor gene WWOX is mutated in an early lethal microcephaly syndrome with epilepsy, growth retardation and retinal degeneration. Orphanet J. Rare Dis. 2014, 9(1):12.
103. Suzuki H., Katayama K., Takenaka M., Amakasu K., Saito K., Suzuki K. A spontaneous mutation of the Wwox gene and audiogenic seizures in rats with lethal dwarfism and epilepsy. Genes Brain Behav. 2009, 8(7):650-660.
104. Hodis E., Watson I.R., Kryukov G.V., Arold S.T., Imielinski M., Theurillat J.P., et al. A landscape of driver mutations in melanoma. Cell 2012, 150(2):251-263.
105. Imielinski M., Berger A.H., Hammerman P.S., Hernandez B., Pugh T.J., Hodis E., et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012, 150(6):1107-1120.
106. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489(7417):519-525.
107. Banerji S., Cibulskis K., Rangel-Escareno C., Brown K.K., Carter S.L., Frederick A.M., et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012, 486(7403):405-409.
108. Biankin A.V., Waddell N., Kassahn K.S., Gingras M.C., Muthuswamy L.B., Johns A.L., et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012, 491(7424):399-405.
109. Cancer Genome Atlas Research Network Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013, 499(7456):43-49.
110. Cancer Genome Atlas Research Network Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014, 507(7492):315-322.